

# Multiple Myeloma Hub | Quarter One 2021 Update



PUBLISHED APR 8, 2021  
BY [PRESSAT](#)

The Multiple Myeloma Hub continues to be a platform that supports clinicians and healthcare providers by providing reliable up-to-date coverage of the latest developments within the field.

During this quarter, the Multiple Myeloma Hub has been very busy attending virtual conferences. February saw the 3rd European CAR T-cell Meeting. The Multiple Myeloma Hub attended the 2nd European Myeloma Network (EMN) Meeting for the first time in March, and coverage was well received.

The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in the middle of March, and the Multiple Myeloma Hub provided extensive coverage through articles, live session reporting, and interviews with experts in the field. The National Comprehensive Cancer Network (NCCN) Virtual Annual Conference rounded off this eventful month of conferences. Virtual coverage continues to be very successful, with the Multiple Myeloma Twitter account of the hub growing to over 4,000 followers.

The Multiple Myeloma Hub showcases independent and credible evidence-based literature, drug approvals, case studies, international congress coverage, and expert opinions, and is brought to you by Scientific Education Support (SES). SES strives to build communities and networks to enhance the level of collective knowledge, using multichannel communications to disseminate medical advances.

Guided by an international Steering Committee of world experts, and run in collaboration with the European School of Haematology (ESH), the Multiple Myeloma Hub is a global online resource that provides vital information for treatment teams, including hematologists and oncologists. Our mission is

to provide up-to-date practical and clinical advice to community hematologists and oncologists, and ensure patients with multiple myeloma have access to the latest therapies available.

The Multiple Myeloma Hub would like to welcome its new industry partner Oncopeptides (Bronze), and would like to thank Sanofi (Gold), AbbVie (Silver), Roche/Genentech (Silver), Bristol Myers Squibb (Silver), GSK (Silver), Amgen (Bronze), and Karyopharm Therapeutics (Contributor), for their continued support of the platform.

For further information on the Multiple Myeloma Hub, please visit [multiplemyelomahub.com](https://multiplemyelomahub.com).

For media enquiries or to explore collaboration opportunities, please contact

*Press release distributed by Media Pigeon on behalf of Pressat, on Apr 8, 2021. For more information subscribe and [follow us](#).*

---

## Press Contacts

### 1. **Alison Lancaster**

Editorial

[editorial@pressat.co.uk](mailto:editorial@pressat.co.uk)

---

## Media Assets

### Embedded Media

Visit the [online press release](#) to interact with the embedded media.

<https://mediapigeon.io/newsroom/pressat/releases/en/multiple-myeloma-hub-quarter-one-2021-update-6686>

---

# Pressat

**Newsroom:** <https://mediapigeon.io/newsroom/pressat>

**Website:** <https://pressat.co.uk/>

**Primary Email:** [wire@pressat.co.uk](mailto:wire@pressat.co.uk)

## Social Media

Twitter - <https://twitter.com/pressat/>

Facebook - <https://www.facebook.com/pressatuk/>

Linkedin - <https://www.linkedin.com/company/pressat-co-uk/>

---